MDPHP is believed to act generally as a strong norepinephrine-dopamine reuptake inhibitor (NDRI). Lowered re-uptake of norepinephrine and dopamine ends in higher concentrations of the two catecholamine neurotransmitters during the synaptic cleft, or gap between neurons. The results of this inhibition can be an enhanced and prolonged concentration a